Entera Bio to present EB613 Phase 3 study design at ASBMR meeting

October 8, 2026 8:00 AM

Entera Bio Ltd. (NASDAQ: ENTX) announced that a presentation of the clinical study design for its planned Phase 3 trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found